Sarcopenic Obesity in the Elderly

Sarcopenic Obesity as Risk Factor for Insulin Resistance in the Elderly

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06083909

Enrollment

Registered

2023-10-16

Start date

2022-04-06

Completion date

2023-05-08

Last updated

2023-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Sarcopenic Obesity

Brief summary

Ageing is associated with progressive and generalized loss of muscle mass and muscle function, also known as Sarcopenia. Increasingly, obesity has become a compounding factor in ageing-related sarcopenia. The coexistence of obesity and sarcopenia is termed sarcopenic obesity (SO). Older adults with SO are at higher risks of developing diabetes, hypertension, stroke, cardiovascular diseases, and cognitive dysfunction than those older adults who suffer from sarcopenia alone or obesity alone. However, there is insufficient information with regard to the interplay between obesity and sarcopenia. The primary objective of this study is to investigate the impact of SO on insulin resistance in people aged 65-85. Our hypothesis is that SO positively influences insulin resistance in the elderly. We propose to investigate sarcopenia and obesity as risk factors for insulin resistance in the geriatric (65-85 years old) population.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

This study will include both male and females aged 65-85 years.

Exclusion criteria

1. Lack capacity to consent for the study, or have moderate or severe cognitive impairment; 2. Have difficulty ambulating as evidenced by any one of the following: 1. Difficulty climbing 10 steps without resting; 2. Restricted to a wheelchair 3. Have difficulty performing basic activities of daily living; 4. Have had treatment for cancer in the prior 3 years; 5. Have history of cachexia; 6. Have a history of heart failure; 7. Have a permanent pacemaker in situ (due to magnetic resonance scanning); 8. Have an implanted cardioverter-defibrillator (ICD) in situ; 9. Have had myocardial infarction within the last 6 months; 10. Have any of the following chronic health conditions: peripheral arterial disease prostate cancer, rheumatoid arthritis, autoimmune myositis, chronic obstructive pulmonary disease, and asthma; 11. Are receiving therapy with corticosteroids or immunosuppressants. 12. Are taking direct insulin sensitizers (PPAR-gamma agonists, or thiazolidinediones).

Design outcomes

Primary

Measure	Time frame
To explore the correlation of sarcopenia and obesity on insulin resistance	2 years

Secondary

Measure	Time frame
To explore the correlation between muscle strength and memory loss	2 years
To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk.	2 years

Countries

United States

Outcome results